Companies Anavex Life Sciences
Anavex Life Sciences (AVXL): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Anavex Life Sciences’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,894,453FY2023
- $2,783,700FY2024
- $3,959,085FY2025
CEO total pay was $3,959,085 in fiscal 2025, up from $2,783,700 in fiscal 2024.
FY2025: salary $723,485 · bonus $140,000 · stock awards $0 · option awards $3,083,000
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Missling | $723,485 | $140,000 | $0 | $3,083,000 | $0 | $0 | $12,600 | $3,959,085 |
| Chief Executive Officer | ||||||||
| Sandra Boenisch | 199,858 | 37,709 | 0 | 308,200 | 0 | 0 | 9,503 | 555,270 |
| Principal Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Christopher Missling | $3,959,085 | $2,783,700 | $3,894,453 | ↑ +1,175,385 |
| Sandra Boenisch | 555,270 | 402,227 | 501,058 | ↑ +153,043 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation program is designed to attract and retain talent, reward excellent performance, and create incentives for stockholder value creation. The Compensation Committee believes a significant portion of compensation should be tied to variable compensation and long-term value creation to balance financial security with performance-based rewards.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Christopher Missling | OPTION | 2025-03-31 | — | — | 500,000 | — | $3,083,000 |
| Sandra Boenisch | OPTION | 2025-03-31 | — | — | 50,000 | — | 308,200 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Christopher Missling | $0 | $0 | $3,083,000 | 0.0% |
| Sandra Boenisch | 0 | 0 | 308,200 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sandra Boenisch | Option | 20,000 | 10.09 | — |
| Sandra Boenisch | Option | 25,000 | 8.57 | — |
| Sandra Boenisch | Option | 37,500 | 5.36 | — |
| Sandra Boenisch | Option | 37,500 | 8.58 | — |
| Sandra Boenisch | Option | 40,000 | 18.11 | — |
| Christopher Missling | Option | 250,000 | 8.57 | — |
| Christopher Missling | Option | 250,000 | 10.09 | — |
| Christopher Missling | Option | 333,333 | 7.54 | — |
| Christopher Missling | Option | 375,000 | 5.36 | — |
| Christopher Missling | Option | 375,000 | 8.58 | — |
| Christopher Missling | Option | 500,000 | 18.11 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Claus van der VeldenIndependent · Audit (Chair) · Nominating and Corporate Governance (Chair) · Compensation (Chair) · Executive | $41,000 | $0 | $323,060 | $0 | $0 | $364,060 |
| Jiong MaIndependent · Board Chair · Audit · Executive | 41,000 | 0 | 323,060 | 0 | 0 | 364,060 |
| Peter DonhauserIndependent · Nominating and Corporate Governance · Compensation | 25,000 | 0 | 323,060 | 0 | 0 | 348,060 |
| Steffen ThomasIndependent · Audit · Nominating and Corporate Governance · Compensation | 25,000 | 0 | 323,060 | 0 | 0 | 348,060 |
| Athanasios SkarpelosIndependent · Departed during FY | 25,000 | 0 | 323,060 | 0 | 0 | 348,060 |
| Axel PaegerIndependent · Executive · Partial-year service · Newly elected | — | — | — | — | — | — |
| Gautam PatelIndependent · Partial-year service | — | — | — | — | — | — |
| Adrian SenderowiczIndependent · Partial-year service · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $25,000 |
|---|---|
| Annual equity retainer | $50,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 16,000 / 16,000 / 16,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $157,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $157,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Anavex Life Sciences as a peer
Companies that benchmark against AVXL
5 companies name AVXL as a compensation peer
The list of companies that name AVXL as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Anavex Life Sciences | 2025 | Christopher Missling | $723,485 | $0 | $3,083,000 | $0 | $3,959,085 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-18 | 28,406,111 | 4,728,255 | 759,625 | 83.81% | Passed |
| 2021 | 2021-05-25 | 29,900,319 | 3,212,520 | 826,667 | 88.1% | Passed |
| 2018 | 2018-04-17 | 9,907,130 | 2,958,367 | 237,974 | 77.01% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-18 | 83.81%a |
| 2021 | 2021-05-25 | 88.1%b |
| 2018 | 2018-04-17 | 77.01%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be treated as votes cast and will have no impact on the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted as votes present and entitled to vote on the proposals considered at the Annual Meeting and, therefore, will have the effect of votes against Proposals 2, 3, 4 and 5.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 16 : 1 |
|---|---|
| CEO total compensation | $3,959,085 |
| Median employee compensation | $248,195 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Sandra Boenisch | PFO & Treasurer | 2026-09-24 | A | 25,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Boenisch | PFO & Treasurer | 2026-09-24 | A | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Boenisch | PFO & Treasurer | 2026-09-24 | A | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Boenisch | PFO & Treasurer | 2026-09-24 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (24 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Christopher Missling. DEF 14A, filed 2026-08-11. Section “Executive Compensation” · page 29. As printed: 3,959,085. View filing ↗
- Section 01, Sandra Boenisch. DEF 14A, filed 2026-08-11. Section “Executive Compensation”. As printed: 555,270. View filing ↗
- Section 03, Christopher Missling OPTION. DEF 14A, filed 2026-08-11. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Sandra Boenisch OPTION. DEF 14A, filed 2026-08-11. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-08-11. Section “CEO Pay Ratio”. As printed: 16 : 1. View filing ↗
- Section 08, Claus van der Velden. DEF 14A, filed 2026-08-11. Section “Director Compensation”. As printed: 364,060. View filing ↗
- Section 08, Jiong Ma. DEF 14A, filed 2026-08-11. Section “Director Compensation”. As printed: 364,060. View filing ↗
- Section 08, Peter Donhauser. DEF 14A, filed 2026-08-11. Section “Director Compensation”. As printed: 348,060. View filing ↗
- Section 08, Steffen Thomas. DEF 14A, filed 2026-08-11. Section “Director Compensation”. As printed: 348,060. View filing ↗
- Section 08, Athanasios Skarpelos. DEF 14A, filed 2026-08-11. Section “Director Compensation”. As printed: 348,060. View filing ↗
- Section 08, Axel Paeger. DEF 14A, filed 2026-08-11. Section “Director Compensation”. As printed: —. View filing ↗
- Section 08, Gautam Patel. DEF 14A, filed 2026-08-11. Section “Director Compensation”. As printed: —. View filing ↗
- Section 08, Adrian Senderowicz. DEF 14A, filed 2026-08-11. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, Sandra Boenisch 2026-09-24. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Boenisch 2026-09-24. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Boenisch 2026-09-24. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Boenisch 2026-09-24. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-21. Item 5.07 · say-on-pay result. As reported: 83.81% (votes for as printed: 28,406,111). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-05-28. Item 5.07 · say-on-pay result. As reported: 88.1%. View filing ↗
- Section 06, 2018 vote. Form 8-K, filed 2018-04-20. Item 5.07 · say-on-pay result. As reported: 77.01%. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 157,000 + equity 0 + all other 0 = 157,000, summed across the director compensation table rows.
- Anavex Life Sciences (subject), Section 10b CEO total. DEF 14A, filed 2026-08-11. CEO total compensation as printed in Anavex Life Sciences's own proxy. As printed: 3,959,085. View filing ↗